Table 1.
Patients’ pretreatment characteristics and risk of venous thromboembolism on univariate analysis
| Variable | Total patients | Patients with VTE |
Risk of time to VTE |
||
| HR | 95%CI | P value | |||
| Total, n (%) | 241 (100.0) | 27 (11.2) | |||
| Age (yr) | |||||
| < 65 | 178 (73.9) | 18 (10.1) | |||
| ≥ 65 | 63 (26.1) | 9 (14.3) | 1.632 | 0.732-3.641 | 0.231 |
| Gender | |||||
| Male | 169 (70.1) | 18 (10.7) | |||
| Female | 72 (29.9) | 9 (12.5) | 1.052 | 0.472-2.345 | 0.9 |
| ECOG PS | |||||
| 0-1 | 229 (95.0%) | 27 (11.8) | |||
| 2 | 12 (5.0%) | 0 | 0.046 | 0.000-99.991 | 0.432 |
| BMI | |||||
| < 25 | 202 (83.8) | 23 (11.4) | |||
| ≥ 25 | 39 (16.2) | 4 (10.3) | 0.793 | 0.274-2.296 | 0.669 |
| Previous CVC | |||||
| No | 233 (96.7) | 25 (10.7) | |||
| Yes | 8 (3.3) | 2 (25.0) | 3.13 | 0.738-13.266 | 0.122 |
| Previous gastrectomy | |||||
| No | 209 (86.7) | 26 (12.4) | |||
| Yes | 32 (13.3) | 1 (3.1) | 0.196 | 0.027-1.448 | 0.11 |
| Primary tumor site | |||||
| Antrum/pylorus | 94 (39.0) | 10 (10.6) | |||
| Body | 32 (13.3) | 9 (11.0) | 1.131 | 0.458-2.791 | 0.79 |
| Cardia/fundus | 28 (11.6) | 3 (10.7) | 1.138 | 0.313-4.144 | 0.844 |
| Diffuse | 25 (10.4) | 5 (20.0) | 2.413 | 0.823-7.073 | 0.108 |
| Histology | |||||
| W/D or M/D | 84 (34.9) | 6 (7.1) | |||
| P/D or SRC | 154 (63.9) | 21 (13.6) | 2.084 | 0.840-5.166 | 0.113 |
| Unclassified | 3 (1.2) | 0 | NA | ||
| Peritoneal seeding | |||||
| No | 137 (56.8) | 11 (8.0) | |||
| Yes | 104 (43.2) | 16 (15.4) | 1.945 | 0.902-4.191 | 0.09 |
| Liver metastasis | |||||
| No | 156 (64.7) | 20 (12.8) | |||
| Yes | 85 (35.3) | 7 (8.2) | 0.741 | 0.313-1.754 | 0.495 |
| Lung metastasis | |||||
| No | 220 (91.3) | 26 (11.8) | |||
| Yes | 21 (8.7) | 1 (4.8) | 0.509 | 0.069-3.764 | 0.509 |
| Bone metastasis | |||||
| No | 225 (93.4) | 24 (10.7) | |||
| Yes | 16 (6.6) | 3 (18.8) | 2.344 | 0.701-7.835 | 0.167 |
| Number of metastatic sites | |||||
| 0-1 | 109 (45.2) | 9 (8.3) | |||
| ≥ 2 | 132 (54.8) | 18 (13.6) | 1.898 | 0.851-1.898 | 0.118 |
| CEA (log) median (range, ng/mL) | 2.5 (0.3-8070) | 1.133 | 0.947-1.355 | 0.173 | |
| CA19-9 (log) median (range, U/mL) | 19.3 (1.4-30800) | 0.882 | 0.726-1.073 | 0.209 | |
| CA72-4 (log) median (range, U/mL) | 5.1 (1.7-6490) | 1.099 | 0.885-1.364 | 0.395 | |
| Hb median (range, g/dL) | 12.0 (7.0-17.6) | 0.956 | 0.786-1.163 | 0.653 | |
| WBC median (range, × 109/L) | 7100 (2600-19300) | 1 | 1.000-1.000 | 0.026 | |
| Platelet median (range, × 109/L) | 274 (107-731) | 1.001 | 0.998-1.005 | 0.508 | |
| CRP median (range, mg/dL) | 2.01 (0.10-19.22) | 1.056 | 0.952-1.053 | 0.302 | |
| Fibrinogen (log) median (range, × 109/L) | 360 (66-897) | 1.132 | 0.337-3.796 | 0.841 | |
| PAI-1 (log) median (range, × 109/L) | 35.0 (2.0-112.0) | 1.197 | 0.662-2.165 | 0.551 | |
| D-dimer (log) median (range, × 109/L) | 1.02 (0.06-82.3) | 1.401 | 1.069 1.836 | 0.015 | |
BMI: Body mass index; CI: Confidence interval; CRP: C-reactive protein; CVC: Central venous catheter; log: Log-transformation; M/D: Moderate differentiation; P/D: Poor differentiation; SRC: Signet ring cell; VTE: Venous thromboembolism; W/D: Well-differentiated.